“Efficacy and Safety of up to Two Years of Tralokinumab Treatment in Adults of Different Racial Subgroups With Moderate-to-Severe Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, p. s74, https://doi.org/10.25251/skin.6.supp.74.